US 12,071,633 B2
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
Brian Furmanski, Morrisville, NC (US); Nachiketa Gupta, Morrisville, NC (US); Bruce Schnepp, Morrisville, NC (US); and Michele Stone, Morrisville, NC (US)
Assigned to Kriya Therapeutics, Inc., Morrisville, NC (US)
Filed by KRIYA THERAPEUTICS, INC., Morrisville, NC (US)
Filed on Oct. 13, 2021, as Appl. No. 17/500,898.
Claims priority of provisional application 63/182,632, filed on Apr. 30, 2021.
Claims priority of provisional application 63/141,921, filed on Jan. 26, 2021.
Claims priority of provisional application 63/108,838, filed on Nov. 2, 2020.
Claims priority of provisional application 63/091,270, filed on Oct. 13, 2020.
Prior Publication US 2022/0162638 A1, May 26, 2022
Int. Cl. C12N 15/86 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 38/208 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C12N 2750/14132 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01); C12N 2830/008 (2013.01); C12N 2840/203 (2013.01)] 15 Claims
 
1. A combination therapy comprising: (a) a first composition comprising an adeno-associated virus (AAV) vector comprising a polynucleotide comprising (i) a promoter, (ii) a first nucleic acid encoding a first Interleukin-12 (IL-12) subunit or functional fragment thereof, (iii) a translation modification sequence, (iv) a second nucleic acid encoding a second IL-12 subunit or functional fragment thereof, (v) a poly(A) (pA) sequence, and (vi) two inverted terminal repeat (ITR) sequences; and (b) a second composition comprising a checkpoint inhibitor, wherein the first nucleic acid comprises SEQ ID NO: 77 and the second nucleic acid comprises SEQ ID NO: 8.